HelixBind awarded up to $2M from CARB- X to combat the rise of antimicrobial resistant pathogens. For more information:
HelixBind closes $3M in Series-A financing
HelixBind awarded a $2.0M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.
USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis
HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens
HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours. For more information:
HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)
HelixBind closes $1.65M seed financing